XFOR
X4 Pharmaceuticals Inc
2.80$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | +0.0% | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | -0.5% | +156.1% | +1,908.9% | -93.2% | -10.5% | +45.5% | +5.5% | +225.2% | – | |
| – | – | – | +0.0% | +8.3% | -9.6% | -44.7% | -3.8% | +4.0% | +0.0% | -23.1% | +20.0% | +12.5% | +585.2% | – | – | +81.6% | -4.8% | +6.6% | +16.0% | +0.8% | +0.6% | +1.0% | +0.2% | -1.2% | +1.4% | +2.2% | +0.8% | -2.7% | -87.6% | +0.0% | +645.2% | -33.5% | -1.6% | +1,557.3% | -90.1% | -24.3% | +3.5% | +54.5% | +170.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -107.6% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +150.5% | +347.4% | +2,002.7% | -93.8% | -5.9% | +56.8% | -3.3% | +240.7% | – | |
| – | +67.1% | +3.9% | -11.0% | +171.4% | -12.9% | -48.6% | +0.2% | +29.5% | -23.9% | +20.6% | +56.6% | -3.0% | -17.7% | +26.1% | +2.3% | +20.3% | +8.5% | -1.8% | +8.7% | -0.1% | -8.1% | +16.7% | -2.2% | +2.2% | +36.0% | +16.4% | -30.0% | +23.2% | -18.1% | +30.1% | +4.7% | -7.9% | +13.7% | -16.0% | -0.2% | -4.8% | +6.8% | -16.5% | -2.4% | – | |
| – | – | -2.5% | +21.0% | +41.3% | -3.2% | +18.6% | +30.8% | -11.2% | +163.5% | -44.6% | -4.7% | -3.9% | -10.7% | +19.3% | +13.8% | +5.3% | -4.3% | +8.9% | -0.5% | +2.2% | +20.3% | +7.4% | -11.9% | +113.6% | +0.0% | -49.8% | +40.9% | -20.3% | +22.1% | +75.6% | -23.8% | +17.9% | -3.3% | -0.8% | -36.6% | +21.6% | +275.6% | -84.0% | +22.0% | – | |
| – | +36.3% | +12.5% | -3.2% | +189.1% | -28.6% | -47.4% | +4.4% | +34.1% | -5.8% | +29.8% | +28.5% | -3.3% | -16.6% | +24.0% | +7.8% | +14.8% | +4.2% | +1.5% | +5.7% | +0.6% | +0.9% | +13.2% | -5.7% | -2.0% | +27.5% | +14.8% | -12.2% | +5.6% | -5.9% | +48.1% | -8.7% | +2.2% | +6.0% | -9.8% | -16.6% | +4.3% | -10.4% | -13.4% | +5.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +55.0% | +28.7% | -56.4% | -22.7% | -20.4% | -38.1% | -1.2% | -11.4% | +59.5% | +69.1% | +28.3% | +34.4% | -20.3% | +6.6% | +17.6% | +1.5% | +3.3% | +23.8% | +1.6% | +1.7% | +0.5% | -1.3% | +0.5% | +10.9% | +12.4% | -3.1% | +3.5% | +42.3% | +15.4% | -0.6% | +16.1% | +10.9% | -4.6% | -4.5% | +1.4% | +1.1% | -3.1% | -2.4% | +1.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -140.4% | – | – | -8,234.2% | – | – | – | – | – | |
| – | – | +26.0% | -59.1% | +3.1% | -43.4% | -20.6% | +34.7% | -2.7% | -2.0% | +60.9% | +65.7% | +12.0% | -118.4% | – | -144.6% | – | -100.0% | – | +0.0% | -66.7% | +50.0% | +666.7% | -82.6% | -425.0% | – | -71.4% | +275.0% | +73.3% | +26.9% | -42.4% | -5.3% | -16.7% | +1,620.0% | -86.8% | +8.8% | -181.1% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -140.4% | – | – | -9,228.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -136.5% | – | – | -868.6% | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.